Alan J. Cross, PhD

Alan Cross is the Chief Scientific Officer at Psy Therapeutics and Chair of their Scientific Advisory Board. At Psy Therapeutics, along with a team of scientific experts, he has built and advanced a portfolio of novel projects in the area of neuropsychiatry and neurodegeneration.

Dr. Cross has over 40 years of research experience within academia and the pharmaceutical industry, following a consistent path of understanding the pathophysiology of neuropsychiatric and neurodegenerative disorders and translating this into drug discovery and development programs. Dr. Cross has led research teams from the very early phases of target identification through lead optimization, candidate drug selection for clinical study and into human translational neuroscience and clinical development. Dr. Cross was Chief Scientist and Disease Area Leader in Psychiatry at  AstraZeneca and a founding member of AstraZeneca Neuroscience Unit in Cambridge MA, which pioneered a ‘virtual drug discovery’ model.